The primary objective of the RECAP Study Program is to investigate the role played by conscious experience in the antidepressant of the psychedelic agent psilocybin. This pilot dosing study is designed to determine the optimal dose of midazolam that allows a psychedelic experience while inducing amnesia for the experience. This is an essential step required for subsequent evaluation of the role of memory for the psychedelic experience in the antidepressant effects of psilocybin.
March 14, 2021
How Important is the ‘Psychedelic’ in Psychedelic Drug Therapies?
November 7, 2019
Can a Trip-Free Psychedelic Still Help People With Depression?